AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

Claims 1-5. (Cancelled).

Claim 6. (Currently Amended) A method for augmenting tumor-specific immune responses by increasing the number of dendritic cells in a patient having a cancerous or neoplastic disease, comprising administering flt3-ligand to the patient for a period of 14 to 19 days~~duration of time~~ and an amount sufficient to generate an increase in the number of the patient's dendritic cells and administering a tumor antigen to the patient,

wherein the tumor antigen is specific for said disease and wherein the resulting dendritic cells augment specific immune responses to said tumor in said patient,

wherein said flt3-ligand comprises a polypeptide that is at least 90% identical to an amino acid sequence selected from the group consisting of amino acids 28 to Xaa of SEQ ID NO:1 wherein Xaa is an amino acid from 160 to 235, and wherein the polypeptide retains the capacity to bind flt3.

Claim 7. (Previously Presented) The method according to claim 6, further comprising administering GM-CSF to the patient.

Claims 8-19. (Cancelled).

Claim 20. (Currently Amended) A method for treating cancerous or neoplastic disease by increasing the number of dendritic cells in a patient in need thereof, comprising administering to a patient afflicted with a cancer or neoplastic

disease, flt3-ligand for a period of 14 to 19 days ~~duration of time~~ and an amount sufficient to generate an increase in the number of the patient's dendritic cells, and administering a tumor antigen to the patient,

wherein said tumor antigen is specific for said disease and wherein the resulting dendritic cells augment specific immune responses to said tumor in said patient to thereby treat said disease,

wherein said flt3-ligand comprises a polypeptide that is at least 90% identical to an amino acid sequence selected from the group consisting of amino acids 28 to Xaa of SEQ ID NO:1 wherein Xaa is an amino acid from 160 to 235, and wherein the polypeptide retains the capacity to bind flt3.

Claim 21. (Cancelled).

Claim 22. (Previously Presented) The method of claim 6, wherein the flt3-ligand is human flt3-ligand.

Claim 23. (Previously Presented) The method of claim 22, wherein the flt3-ligand is soluble human flt3-ligand.

Claim 24. (Previously Presented) The method of claim 23, wherein the soluble human flt3-ligand is recombinant flt3-ligand.

Claim 25-27. (Cancelled).

Claim 28. (Previously Presented) The method of claim 6, wherein the flt3-ligand comprises the amino acid sequence of residues 28-160 of SEQ ID NO:1.

Claim 29. (Cancelled).

Claim 30. (Previously Presented) The method of claim 6, wherein the flt3-ligand comprises the amino acid sequence of residues 28-182 of SEQ ID NO:1.

Claim 31. (Previously Presented) The method of claim 20, wherein the flt3-ligand is human flt3-ligand.

Claim 32. (Previously Presented) The method of claim 31, wherein the flt3-ligand is soluble human flt3-ligand.

Claim 33. (Previously Presented) The method of claim 32, wherein the soluble human flt3-ligand is recombinant flt3-ligand.

Claim 34. (Previously Presented) The method of claim 20, wherein the human flt3-ligand comprises the amino acid sequence of residues 28-160 of SEQ ID NO:1.

Claim 35. (Previously Presented) The method of claim 20, wherein the human flt3-ligand comprises the amino acid sequence of residues 28-182 of SEQ ID NO:1.

Claim 36-39. (Cancelled).

Claim 40. (Previously Presented) The method of claim 6 wherein the cancerous disease is a tumor.

Claim 41. (Previously Presented) The method of claim 20 wherein the cancerous disease is a tumor.

Claim 42. (Previously Presented) The method of claim 40 wherein the tumor is a fibrosarcoma.

Claim 43. (Previously Presented) The method of claim 41 wherein the tumor is a fibrosarcoma.

Claim 44. (Previously Presented) The method of claim 6, wherein the tumor antigen is in the form of a tumor cell bearing said tumor antigen.

Claim 45. (Previously Presented) The method of claim 6, wherein the tumor antigen is in the form of an isolated tumor antigen.

Claim 46. (Previously Presented) The method of claim 6, wherein the antigen is administered prior to administering flt3-ligand.

Claim 47. (Previously Presented) The method of claim 6, wherein the antigen is administered concurrently with flt3-ligand.

Claim 48. (Previously Presented) The method of claim 6, wherein the antigen is administered after administering flt3-ligand.

Claim 49. (Previously Presented) The method of claim 20, wherein the tumor antigen is in the form of a tumor cell bearing said tumor antigen.

Claim 50. (Previously Presented) The method of claim 20, wherein the tumor antigen is in the form of an isolated tumor antigen.

Claim 51. (Previously Presented) The method of claim 20, wherein the tumor antigen is administered prior to administering flt3-ligand.

Claim 52. (Previously Presented) The method of claim 20, wherein the tumor antigen is administered concurrently with administering flt3-ligand.

Claim 53. (Previously Presented) The method of claim 20, wherein the tumor antigen is administered after administering flt3-ligand.

Claim 54-56. (Cancelled).